Details for New Drug Application (NDA): 208137
✉ Email this page to a colleague
NDA 208137 describes DOCETAXEL, which is a drug marketed by Accord Hlthcare, Actavis, Alembic, Amneal, Apotex Inc, Dfb Oncology Ltd, Dr Reddys, Eugia Pharma, Gland Pharma Ltd, Hengrui Pharma, Heritage, Hikma, Hospira Inc, Meitheal, Mylan Labs Ltd, Norvium Bioscience, Novast Labs, Pfizer Labs, Sandoz, Shilpa, Sun Pharm, and Teva Pharms Usa, and is included in twenty-seven NDAs. It is available from nineteen suppliers. There are four patents protecting this drug. Additional details are available on the DOCETAXEL profile page.
The generic ingredient in DOCETAXEL is docetaxel. There are forty-one drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the docetaxel profile page.
The generic ingredient in DOCETAXEL is docetaxel. There are forty-one drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the docetaxel profile page.
Summary for 208137
| Tradename: | DOCETAXEL |
| Applicant: | Mylan Labs Ltd |
| Ingredient: | docetaxel |
| Patents: | 0 |
Pharmacology for NDA: 208137
| Physiological Effect | Microtubule Inhibition |
Suppliers and Packaging for NDA: 208137
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 208137 | ANDA | Mylan Institutional LLC | 67457-781 | 67457-781-08 | 1 VIAL, MULTI-DOSE in 1 CARTON (67457-781-08) / 8 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 160MG/8ML (20MG/ML) | ||||
| Approval Date: | Apr 1, 2019 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
